Genes,
Journal Year:
2019,
Volume and Issue:
10(9), P. 654 - 654
Published: Aug. 28, 2019
Inherited
retinal
diseases
(IRDs)
are
both
genetically
and
clinically
highly
heterogeneous
have
long
been
considered
incurable.
Following
the
successful
development
of
a
gene
augmentation
therapy
for
biallelic
RPE65-associated
IRD,
this
view
has
changed.
As
result,
many
different
therapeutic
approaches
currently
being
developed,
in
particular
large
variety
molecular
therapies.
These
depending
on
severity
degeneration,
knowledge
pathophysiological
mechanism
underlying
each
subtype
target
molecule.
DNA
therapies
include
such
as
therapy,
genome
editing
optogenetics.
For
some
genetic
subtypes
RNA
compound
also
shown
considerable
potential.
In
review,
we
summarize
current
state-of-the-art
various
approaches,
including
pros
cons
strategy,
outline
future
challenges
that
lie
ahead
combat
against
IRDs.
Progress in Retinal and Eye Research,
Journal Year:
2021,
Volume and Issue:
86, P. 100975 - 100975
Published: May 29, 2021
Inherited
and
age-related
retinal
degeneration
is
the
hallmark
of
a
large
group
heterogeneous
diseases
main
cause
untreatable
blindness
today.
Genetic
factors
play
major
pathogenic
role
in
degenerations
for
both
monogenic
(such
as
retinitis
pigmentosa)
complex
with
established
genetic
risk
macular
degeneration).
Progress
genotyping
techniques
back
eye
imaging
are
completing
our
understanding
these
their
manifestations
patient
populations
suffering
from
degenerations.
It
clear
that
whatever
cause,
majority
vision
loss
results
photoreceptor
function.
The
timing
circumstances
surrounding
function
determine
adequate
therapeutic
approach
to
use
each
patient.
Among
such
approaches,
gene
therapy
rapidly
becoming
reality
applicable
clinic.
This
massive
move
laboratory
work
towards
clinical
application
has
been
propelled
by
advances
disease
genetics
mechanisms,
delivery
vectors,
editing
systems,
compensatory
strategies
Here,
we
provide
an
overview
existing
modalities
relevance
based
on
needs
inherited
Molecular Therapy,
Journal Year:
2017,
Volume and Issue:
25(11), P. 2546 - 2560
Published: July 20, 2017
The
majority
of
inherited
retinal
degenerations
converge
on
the
phenotype
photoreceptor
cell
death.
Second-
and
third-order
neurons
are
spared
in
these
diseases,
making
it
possible
to
restore
light
responses
using
optogenetics.
Viral
expression
channelrhodopsin
under
ubiquitous
promoters
was
previously
shown
visual
function,
albeit
at
intensities
above
illumination
safety
thresholds.
Here,
we
report
(to
our
knowledge,
for
first
time)
activation
macaque
retinas,
up
6
months
post-injection,
channelrhodopsin-Ca2+-permeable
(CatCh)
safe
intensities.
High-level
CatCh
achieved
due
a
new
promoter
based
regulatory
region
gamma-synuclein
gene
(SNCG)
allowing
strong
ganglion
cells
across
species.
Our
promoter,
combination
with
clinically
proven
adeno-associated
virus
2
(AAV2),
provides
peri-foveolar
responding
robustly
thresholds
human
eye.
On
contrary,
threshold
proportion
unresponsive
were
much
higher
when
(cytomegalovirus
[CMV])
used
express
CatCh.
results
study
suggest
that
inclusion
optimized
is
key
path
clinical
translation
Nature Communications,
Journal Year:
2019,
Volume and Issue:
10(1)
Published: March 15, 2019
Abstract
Inherited
and
age-related
retinal
degenerative
diseases
cause
progressive
loss
of
rod
cone
photoreceptors,
leading
to
blindness,
but
spare
downstream
neurons,
which
can
be
targeted
for
optogenetic
therapy.
However,
approaches
have
been
limited
by
either
low
light
sensitivity
or
slow
kinetics,
lack
adaptation
changes
in
ambient
light,
not
shown
restore
object
vision.
We
find
that
the
vertebrate
medium
wavelength
opsin
(MW-opsin)
overcomes
these
limitations
supports
vision
dim
light.
MW-opsin
enables
an
otherwise
blind
retinitis
pigmenotosa
mouse
discriminate
temporal
spatial
patterns
displayed
on
a
standard
LCD
computer
tablet,
displays
adaption
restores
open-field
novel
exploration
under
incidental
room
By
contrast,
rhodopsin,
is
similar
slower
response
has
greater
rundown,
fails
tests.
Thus,
provides
speed,
needed
patterned
JCI Insight,
Journal Year:
2018,
Volume and Issue:
3(2)
Published: Jan. 24, 2018
Intraocular
injection
of
adeno-associated
viral
(AAV)
vectors
has
been
an
evident
route
for
delivering
gene
drugs
into
the
retina.
However,
gaps
in
our
understanding
AAV
transduction
patterns
within
anatomically
unique
environments
subretinal
and
intravitreal
space
primate
eye
impeded
establishment
noninvasive
efficient
delivery
to
foveal
cones
clinic.
Here,
we
establish
new
vector-promoter
combinations
overcome
limitations
associated
with
AAV-mediated
cone
fovea
supporting
studies
mouse
models,
human
induced
pluripotent
stem
cell–derived
organoids,
postmortem
retinal
explants,
living
macaques.
We
show
that
AAV9
variant
provides
when
injected
several
millimeters
away
from
fovea,
without
detaching
this
delicate
region.
An
engineered
AAV2
a
well-tolerated
dose
administered
intravitreally.
Both
modalities
rely
on
cone-specific
promoter
result
high-level
transgene
expression
compatible
optogenetic
vision
restoration.
The
model
systems
described
here
provide
insight
behavior
across
species
obtain
safety
efficacy
needed
therapy
neurodegenerative
disorders.
Nature Communications,
Journal Year:
2019,
Volume and Issue:
10(1)
Published: Oct. 4, 2019
A
major
challenge
in
the
treatment
of
retinal
degenerative
diseases,
with
transplantation
replacement
photoreceptors,
is
difficulty
inducing
grafted
cells
to
grow
and
maintain
light
sensitive
outer
segments
host
retina,
which
depends
on
proper
interaction
underlying
pigment
epithelium
(RPE).
Here,
for
an
RPE-independent
approach,
we
introduce
a
hyperpolarizing
microbial
opsin
into
photoreceptor
precursors
from
newborn
mice,
transplant
them
blind
mice
lacking
layer.
These
optogenetically-transformed
photoreceptors
are
responsive
their
leads
recovery
visual
function,
as
shown
by
ganglion
cell
recordings
behavioral
tests.
Subsequently,
generate
cone
human
induced
pluripotent
stem
cells,
expressing
chloride
pump
Jaws.
After
observe
light-driven
responses
at
levels.
results
demonstrate
that
structural
functional
repair
possible
combining
therapy
optogenetics.
Communications Biology,
Journal Year:
2021,
Volume and Issue:
4(1)
Published: Jan. 27, 2021
Abstract
Vision
restoration
is
an
ideal
medical
application
for
optogenetics,
because
the
eye
provides
direct
optical
access
to
retina
stimulation.
Optogenetic
therapy
could
be
used
diseases
involving
photoreceptor
degeneration,
such
as
retinitis
pigmentosa
or
age-related
macular
degeneration.
We
describe
here
selection,
in
non-human
primates,
of
a
specific
optogenetic
construct
currently
tested
clinical
trial.
microbial
opsin
ChrimsonR,
and
showed
that
AAV2.7m8
vector
had
higher
transfection
efficiency
than
AAV2
retinal
ganglion
cells
(RGCs)
ChrimsonR
fused
tdTomato
(ChR-tdT)
was
expressed
more
efficiently
ChrimsonR.
Light
at
600
nm
activated
RGCs
transfected
with
ChR-tdT,
from
irradiance
10
15
photons.cm
−2
.s
−1
.
Vector
doses
5
×
11
vg/eye
up
7000
RGCs/mm
2
perifovea,
no
significant
immune
reaction.
recorded
RGC
responses
stimulus
duration
1
ms
upwards.
When
using
activity
decode
information,
we
obtained
estimated
visual
acuity
20/249,
above
level
legal
blindness
(20/400).
These
results
lay
groundwork
ongoing
trial
-
ChR-tdT
vision
patients
pigmentosa.